NDWG priority addressed
Support the goal of disease elimination by addressing the reservoir of TB infection and efficiently introduce targeted preventive therapy.
Required tests: Tests for better detection of tuberculosis infection (TBI) and for predicting the risk of progression from latent infection to active TB disease (Tests of progression of TBI).
Reactivation of TBI is the source of the vast majority of new TB cases in low transmission areas. As global TB incidence declines, preventing progression from TBI to active TB will become more and more crucial for TB elimination. Treatment of individuals with TBI requires a diagnostic test to identify the small proportion of latently infected persons who will progress to active disease.
Goal and Objectives
Enhance the knowledge base and support consensus-building by engaging participation of key experts and stakeholders towards further development and finalization of the following resources
- Target Product Profile (TPP) for a test of progression of TBI;
- Framework for the evaluation of new TBI tests;
- Viewpoint paper on novel diagnostic tests required to comprehensively accomplish TBI management.
- Model to evaluate the impact of a test for incipient TB
Dr. Alberto Matteelli, University of Brescia, Italy
Task Force members
- Gavin Churchyard, Aurum Institute, South Africa
- Daniela Cirillo, San Raffaele Scientific Institute, Italy (NDWG Co-Chair)
- Frank Cobelens, AIGHD and KNCV, The Netherlands
- Christopher Gilpin, WHO Global TB Programme
- Delia Goletti, National Institute for Infectious Diseases, Italy
- Amita Gupta, Johns Hopkins School of Medicine, United States
- Sandra Kik, Independant Consultant, The Netherlands
- Dick Menzies, McGill, Canada
- Lele Rangaka, University College London, UK
- Samuel Schumacher, FIND, Switzerland